ERAS

Rating neutralAI Memo

Erasca

As of 2026-04-29/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-29 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Post-data safety digestion can keep ERAS-0015 under pressure • 2026-05-15

Base target: $9 / p=45% prob

Biggest risk

The same 8-K disclosed a pneumonitis case that progressed to Grade 5 and repeatedly warned that the data are preliminary, partly pooled across separate trials, include licensor-generated data not independently verified by Erasca, and rely on cross-trial comparisons rather than head-to-head evidence; that keeps the thesis speculative despite the efficacy signals [#8-K-2026-04-27].

Invalidation

Break below $6 or thesis failure.

What would change my mind?

Primary-source evidence is not purely negative: the April 27 8-K reported dose-dependent PK, broad ctDNA reductions, strong early unconfirmed response rates in NSCLC and PDAC, selected 24 mg and 32 mg as go-forward monotherapy RDEs, and showed early combinability signals, while the 10-K said cash plus January 2026 financing proceeds less the Joyo payment should fund operations into the second half of 2028 [#8-K-2026-04-27] [#10-K-2026-03-12].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-04-29

Base target

p=45%

Bull target

$13

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-data safety digestion can keep ERAS-0015 under pressure
ERAS-4001 initial Phase 1 monotherapy data remains the next cleaner pipeline readout
ERAS-0015 expansion and combination data are now the bigger proof point

BearKey bullets

A treatment-related pneumonitis event progressed to Grade 5 after supportive-care withdrawal, creating a real safety overhang around ERAS-0015 [#8-K-2026-04-27].
Clinical timing risk remains meaningful because AURORAS-1 and BOREALIS-1 readouts could be delayed or fail to confirm the current early signal [#8-K-2026-04-27].
ERAS-0015 efficacy framing depends on preliminary pooled data and cross-trial comparisons, which the company itself cautioned are inherently limited and may change with follow-up [#8-K-2026-04-27].

WatchKey bullets

The packet’s median analyst target is $11.5 versus a $9.9 anchor price, implying only modest headline upside after the selloff; target count and fresh post-event revisions were unavailable, so valuation support looks thin until analysts and investors digest the safety/benefit trade-off.

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $9 (p=45%)

Target spread vs base: +53% / -35%

Scenario probabilities

Bull Target: $13 (p=25%)Base Target: $9 (p=45%)Bear Target: $6 (p=30%)

Commentary

Headline tone turned sharply negative after the April 27, 2026 filing, with April 28 coverage emphasizing the patient death and large sell-off rather than the response-rate data. Primary sources support both the efficacy signal and the safety issue, but low coverage, unavailable fresh analyst revisions, and a negative deterministic prior argue for a cautious monitoring stance instead of treating the drop as a clear dislocation buy.

As of 2026-04-29 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-data safety digestion can keep ERAS-0015 under pressure
ERAS-4001 initial Phase 1 monotherapy data remains the next cleaner pipeline readout
ERAS-0015 expansion and combination data are now the bigger proof point

Scenarios

Bull Target (Scenario probability)

$13 / p=25% prob

Base Target (Scenario probability)

$9 / p=45% prob

Bear Target (Scenario probability)

$6 / p=30% prob

Analysis 2026-04-29 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.75

Social Sentiment (7d)

0.00

Short-term Catalysts

Next few weeks

Post-data safety digestion can keep ERAS-0015 under pressure
2026-05-15
The April 27, 2026 8-K paired strong preliminary response data with a Grade 3 pneumonitis case that progressed to Grade 5 after withdrawal of supportive care, which can continue to dominate near-term investor framing despite otherwise favorable early activity and tolerability metrics [#8-K-2026-04-27].
Prob 75% • Move 15% • Priced-in 70%

Long-term Catalysts

Months to a year

ERAS-4001 initial Phase 1 monotherapy data remains the next cleaner pipeline readout
2026-12-31
The company said preliminary Phase 1 monotherapy data from BOREALIS-1 for pan-KRAS inhibitor ERAS-4001 is expected in the second half of 2026, giving investors a separate efficacy readout not tied to the April ERAS-0015 safety debate [#8-K-2026-04-27].
Prob 60% • Move 30% • Priced-in 35%
ERAS-0015 expansion and combination data are now the bigger proof point
2027-06-30
Erasca said it initiated ERAS-0015 monotherapy expansion and combination dose-escalation cohorts ahead of prior guidance, with monotherapy expansion data and combination dose-escalation data expected in the first half of 2027; stronger durability and combination evidence would be needed to overcome cross-trial-comparison skepticism [#8-K-2026-04-27].
Prob 55% • Move 40% • Priced-in 30%

Risks

A treatment-related pneumonitis event progressed to Grade 5 after supportive-care withdrawal, creating a real safety overhang around ERAS-0015 [#8-K-2026-04-27].
Clinical timing risk remains meaningful because AURORAS-1 and BOREALIS-1 readouts could be delayed or fail to confirm the current early signal [#8-K-2026-04-27].
ERAS-0015 efficacy framing depends on preliminary pooled data and cross-trial comparisons, which the company itself cautioned are inherently limited and may change with follow-up [#8-K-2026-04-27].
Erasca remains pre-revenue and loss-making, so if development slips or safety issues expand, current runway assumptions could tighten despite guidance into the second half of 2028 [#10-K-2026-03-12].

Peers

Symbol	Summary
RVMD	Most relevant operating read-through because Erasca’s 8-K explicitly benchmarked ERAS-0015 against Revolution Medicines comparator data; useful for judging whether ERAS-0015 is differentiated enough to justify valuation recovery.
IOVA	Useful small-cap oncology comparator for binary clinical sentiment and financing sensitivity, though it is not a mechanism match and should be treated as a loose risk-appetite peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-04-29

Loading AI feed…

Symbol

Summary

RVMD

Most relevant operating read-through because Erasca’s 8-K explicitly benchmarked ERAS-0015 against Revolution Medicines comparator data; useful for judging whether ERAS-0015 is differentiated enough to justify valuation recovery.

IOVA

Useful small-cap oncology comparator for binary clinical sentiment and financing sensitivity, though it is not a mechanism match and should be treated as a loose risk-appetite peer.